5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Thrombocytopenia O
, O
neutropenia O
, O
and O
anemia O
: O
Monitor O
blood O
counts O
and O
omit O
and/or O
reduce O
dose O
for O
hematologic O
toxicities O
. O

( O
2.2 O
, O
5.1 O
) O
* O
Mucositis O
: O
Monitor O
at O
least O
weekly O
. O

If O
> O
= O
Grade O
2 O
mucositis O
is O
observed O
, O
omit O
and/or O
reduce O
dose O
. O

( O
2.2 O
, O
5.2 O
) O
* O
Dermatologic O
reactions O
: O
Reactions O
, O
including O
fatal O
reactions O
, O
have O
occurred O
and O
may O
be O
progressive O
and O
increase O
in O
severity O
with O
further O
treatment O
. O

Monitor O
closely O
, O
and O
omit O
and/or O
reduce O
dose O
or O
discontinue O
FOLOTYN O
. O

( O
2.2 O
, O
5.3 O
) O
* O
Tumor O
lysis O
syndrome O
: O
Anticipate O
, O
monitor O
, O
and O
treat O
promptly O
. O

( O
5.4 O
) O
* O
Hepatic O
toxicity O
: O
Monitor O
for O
toxicity O
. O

For O
liver O
function O
test O
abnormalities O
Grade O
3 O
or O
greater O
, O
omit O
until O
recovery O
then O
reduce O
dose O
or O
discontinue O
therapy O
as O
required O
. O

( O
2.2 O
, O
5.5 O
) O
* O
Risk O
of O
increased O
toxicity O
with O
renal O
impairment O
: O
Patients O
with O
moderate O
to O
severe O
renal O
function O
impairment O
may O
be O
at O
greater O
risk O
for O
increased O
exposure O
and O
toxicity O
. O

Monitor O
patients O
for O
renal O
function O
and O
systemic O
toxicity O
and O
adjust O
dosing O
accordingly O
. O

Avoid O
FOLOTYN O
use O
in O
patients O
with O
end O
stage O
renal O
disease O
including O
those O
undergoing O
dialysis O
unless O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
. O

( O
2.2 O
, O
5.6 O
, O
6.2 O
) O
* O
Embryo-Fetal O
toxicity O
: O
Women O
should O
avoid O
becoming O
pregnant O
while O
being O
treated O
with O
FOLOTYN O
. O

Inform O
pregnant O
women O
of O
the O
potential O
harm O
to O
the O
fetus O
. O

( O
5.7 O
, O
8.1 O
) O
5.1 O
Bone O
Marrow O
Suppression O
FOLOTYN O
can O
cause O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
suppression I-OSE_Labeled_AE
, O
manifested O
by O
thrombocytopenia B-NonOSE_AE
, O
neutropenia B-NonOSE_AE
, O
and/or O
anemia B-NonOSE_AE
. O

Monitor O
complete O
blood O
counts O
and O
omit O
and/or O
reduce O
the O
dose O
based O
on O
ANC O
and O
platelet O
count O
prior O
to O
each O
dose O
as O
outlined O
in O
Section O
2.2 O
Table O
2 O
. O

Administer O
vitamin O
B12and O
instruct O
patients O
to O
take O
folic O
acid O
to O
reduce O
the O
risk O
of O
treatment-related O
hematological B-NonOSE_AE
toxicity I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.2 O
Mucositis O
FOLOTYN O
can O
cause O
mucositis B-OSE_Labeled_AE
. O

Monitor O
for O
mucositis B-NonOSE_AE
weekly O
and O
if O
> O
= O
Grade O
2 O
mucositis B-NonOSE_AE
is O
observed O
, O
omit O
and/or O
reduce O
the O
dose O
as O
outlined O
in O
Section O
2.2 O
Table O
1 O
. O

Administer O
vitamin O
B12and O
instruct O
patients O
to O
take O
folic O
acid O
to O
reduce O
the O
risk O
of O
mucositis B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
) O
( O
2.2 O
) O
and O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.3 O
Dermatologic O
Reactions O
FOLOTYN O
can O
cause O
severe O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
which O
may O
result O
in O
death B-NonOSE_AE
. O

These O
dermatologic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
have O
been O
reported O
in O
clinical O
studies O
( O
14/663 O
patients O
[ O
2.1 O
% O
] O
) O
and O
post O
marketing O
experience O
, O
and O
have O
included O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
ulceration O
, O
and O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
( O
TEN O
) O
. O

They O
may O
be O
progressive O
and O
increase O
in O
severity O
with O
further O
treatment O
, O
and O
may O
involve O
skin O
and O
subcutaneous O
sites O
of O
known O
lymphoma B-Not_AE_Candidate
. O

Monitor O
patients O
with O
dermatologic B-NonOSE_AE
reactions I-NonOSE_AE
closely O
, O
and O
if O
severe O
, O
withhold O
or O
discontinue O
FOLOTYN O
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
] O
. O

5.4 O
Tumor O
Lysis O
Syndrome O
FOLOTYN O
can O
cause O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
TLS O
) O
. O

Monitor O
patients O
who O
are O
at O
increased O
risk O
of O
TLS B-NonOSE_AE
and O
treat O
promptly O
. O

5.5 O
Hepatic O
Toxicity O
FOLOTYN O
can O
cause O
hepatic B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
test I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
. O

Persistent O
liver B-NonOSE_AE
function I-NonOSE_AE
test I-NonOSE_AE
abnormalities I-NonOSE_AE
may O
be O
indicators O
of O
hepatic B-NonOSE_AE
toxicity I-NonOSE_AE
and O
require O
dose O
modification O
or O
discontinuation O
. O

Monitor O
liver O
function O
tests O
. O

Omit O
dose O
until O
recovery O
, O
adjust O
or O
discontinue O
therapy O
based O
on O
the O
severity O
of O
the O
hepatic B-NonOSE_AE
toxicity I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.6 O
Risk O
of O
Increased O
Toxicity O
in O
the O
Presence O
of O
Impaired O
Renal O
Function O
Patients O
with O
moderate O
to O
severe O
renal B-Not_AE_Candidate
function I-Not_AE_Candidate
impairment I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
for O
increased O
exposure O
and O
toxicity O
. O

Monitor O
patients O
for O
renal O
function O
and O
systemic O
toxicity O
and O
adjust O
dosing O
accordingly O
. O

Serious O
adverse O
drug O
reactions O
including O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
and O
mucositis B-OSE_Labeled_AE
were O
reported O
in O
patients O
with O
end B-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
ESRD O
) O
undergoing O
dialysis O
who O
were O
administered O
FOLOTYN O
therapy O
. O

Avoid O
FOLOTYN O
use O
in O
patients O
with O
end B-Not_AE_Candidate
stage I-Not_AE_Candidate
renal I-Not_AE_Candidate
disease I-Not_AE_Candidate
including O
those O
undergoing O
dialysis O
unless O
the O
potential O
benefit O
justifies O
the O
potential O
risk O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Adverse O
Reactions O
( O
6.2 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.7 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
FOLOTYN O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
. O

FOLOTYN O
was O
embryotoxic B-NonOSE_AE
and O
fetotoxic B-NonOSE_AE
in O
rats O
and O
rabbits O
. O

If O
this O
drug O
is O
used O
during O
pregnancy B-Not_AE_Candidate
, O
or O
if O
the O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
this O
drug O
, O
the O
patient O
should O
be O
apprised O
of O
the O
potential O
hazard B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

